Fig. 1 | Laboratory Investigation

Fig. 1

From: Loss of Fezf2 promotes malignant progression of bladder cancer by regulating the NF-κB signaling pathway

Fig. 1

Fezf2 expression is decreased in bladder cancer. a Fezf2 mRNA expression in 60 pairs of bladder cancer and adjacent non-tumor tissue. b Protein expression of Fezf2 in 10 pairs of randomly selected tumor (T) and adjacent non-tumor tissue (N). c, d Fezf2 mRNA and protein in normal bladder urothelial cells (NBUCs), human uroepithelial cells (SV-HUC-1), and bladder cancer cell lines (BIU-87, T24, J82, UM-UC-3, RT4, EJ, and TCCSUP). e Expression levels of Fezf2 mRNA in tumor and normal tissue of bladder cancer patients from GSE3167 database. f Kaplan–Meier analysis of overall survival curves for bladder cancer patients with negative vs. positive Fezf2 expression. Fezf2 positivity was significantly correlated with more favorable overall survival (P = 0.010) and recurrence-free survival (P = 0.015). OS overall survival, RFS recurrence-free survival. g Representative images of IHC analysis of Fezf2 in bladder cancer specimens. 400×

Back to article page